(Q46837580)

25 December 2017

title

Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease (English)

1 reference

25 December 2017

author name string

Joon Ho Song

1

1 reference

25 December 2017

Seok Ho Cha

2

1 reference

25 December 2017

Hun Jae Lee

3

1 reference

25 December 2017

Seoung Woo Lee

4

1 reference

25 December 2017

Geun Ho Park

5

1 reference

25 December 2017

Seung Won Lee

6

1 reference

25 December 2017

Moon-Jae Kim

7

1 reference

25 December 2017

language of work or name

English

0 references

publication date

5 December 2005

1 reference

25 December 2017

Nephrology Dialysis Transplantation

published in

1 reference

25 December 2017

volume

21

1 reference

25 December 2017

issue

3

1 reference

25 December 2017

page(s)

683-689

1 reference

25 December 2017

Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists

cites work

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Low-dose dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Transforming growth factor beta contributes to progressive diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFI310

21 January 2018

Identifiers

DOI

10.1093/NDT/GFI310

1 reference

25 December 2017

PubMed ID

16330466

1 reference

25 December 2017